Clinical Trials ArenaOriginal article
FDA grants clearance for PhenoNet Phase III trial in early Alzheimer’s
Phase 3approvedPHENOGENE-1APositive
AI Analysis
Summary
PhenoNet received FDA clearance to initiate a Phase III clinical trial of PHENOGENE-1A in patients with early Alzheimer's disease.
Clinical Trial Data
Phase
Phase III
Outcome Details
FDA granted clearance to proceed with Phase III clinical trial
Importance:7/10
Sentiment:
0.80
FDA approvalPhase IIIAlzheimer's diseaseregulatory clearance
Read the original article
Published by Clinical Trials Arena on August 14, 2026 10:11 AM